Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Systemic Lupus Erythematosus
    Intervention:  
    Sponsors:   Monash University;   Flinders Medical Centre, Adelaide, AUSTRALIA;   St. Vincent's Hospital, Melbourne, AUSTRALIA;   Royal Adelaide Hospital, Adelaide, AUSTRALIA;   University of New South Wales, Sydney, AUSTRALIA;   People's Hospital, Peking University Health Science Center, Beijing, CHINA;   Peking University First Hospital, Beijing, CHINA;   The University of Hong Kong, HONG KONG;   University of Padjadjaran, Bandung, INDONESIA;   Tokyo Women's Medical University, JAPAN;   University of Occupational and Environmental Health, JAPAN;   Keio University, JAPAN;   Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA;   University of Malaya;   University of Santo Tomas Hospital, Philippines;   National University Hospital, Singapore;   Tan Tock Seng Hospital;   Chang Gung Memorial Hospital;   Taichung Veterans General Hospital;   Chiang Mai University Hospital, THAILAND;   Dubai Hospital, Dubai, UNITED ARAB EMIRATES;   Middlemore Hospital, New Zealand;   North Shore Hospital, Auckland, NEW ZEALAND;   Auckland District Health Board, Auckland, NEW ZEALAND
    Recruiting

  • Condition:   Safety LTFU, Pts Receiving CD19 Directed CAR T-Cell Therapy
    Intervention:   Genetic: Previously treated CART CD 19 patients
    Sponsors:   Novartis Pharmaceuticals;   University of Pennsylvania
    Recruiting

  • Conditions:   Relapsing Remitting Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
    Intervention:   Biological: ATA188
    Sponsor:   Atara Biotherapeutics
    Recruiting

  • Conditions:   Relapsing Remitting Multiple Sclerosis;   Optic Neuropathy;   Optic; Neuritis, With Demyelination
    Interventions:   Drug: CNM-Au8;   Drug: Placebo
    Sponsors:   Clene Nanomedicine;   Clene Australia Pty Ltd
    Recruiting

  • Condition:   Systemic Lupus Erythematosus
    Intervention:   Other: Standard of Care
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Condition:   Pemphigus
    Interventions:   Drug: PRN1008 Oral Tablet;   Drug: Placebo Oral Tablet
    Sponsor:   Principia Biopharma Inc.
    Recruiting

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept
    Sponsor:   Pfizer
    Recruiting

  • Condition:   IgA Glomerulonephritis
    Interventions:   Drug: methylprednisolone;   Drug: Placebo
    Sponsors:   The George Institute;   Peking University First Hospital
    Recruiting

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Incyte Corporation
    Recruiting

  • Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: LY900014;   Drug: Insulin Lispro
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting

  • Condition:   Relapsing-Remitting Multiple Sclerosis
    Intervention:   Drug: natalizumab
    Sponsor:   Biogen
    Recruiting

  • Condition:   Pemphigus Vulgaris
    Intervention:   Drug: PRN1008
    Sponsors:   Principia Biopharma Inc.;   Principia Biopharma Australia Pty Ltd.
    Recruiting

  • Conditions:   Diabetes;   Diabetes Mellitus, Type 1
    Interventions:   Drug: Insulin degludec;   Drug: Insulin Aspart;   Drug: Insulin detemir
    Sponsor:   Novo Nordisk A/S
    Recruiting

  • Condition:   Systemic Lupus Erythematosus (SLE)
    Interventions:   Drug: VAY736;   Drug: VAY736 Placebo;   Drug: CFZ533;   Drug: CFZ533 Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Intervention:   Drug: Ocrelizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Giant Cell Arteritis (GCA)
    Interventions:   Drug: Upadacitinib;   Drug: Corticosteroid (CS);   Other: Placebo
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Agglutinin Disease, Cold
    Interventions:   Drug: Sutimlimab;   Drug: Placebo
    Sponsor:   Bioverativ Therapeutics Inc.
    Recruiting

  • Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: Upadacitinib matching placebo;   Drug: Abatacept matching placebo;   Drug: Upadacitinib;   Drug: Abatacept
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: Mavenclad®
    Sponsor:   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Condition:   IgA Nephropathy
    Interventions:   Drug: LNP023;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Relapsing Multiple Scelrosis
    Interventions:   Drug: Ofatumumab subcutaneous injection;   Drug: Placebo orally matching to teriflunomide;   Drug: Teriflunomide orally;   Drug: Placebo subcutaneous injection matching to ofatumumab
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Giant Cell Arteritis
    Interventions:   Combination Product: mavrilimumab;   Combination Product: placebo
    Sponsor:   Kiniksa Pharmaceuticals, Ltd.
    Recruiting

  • Condition:   Diffuse Cutaneous Systemic Sclerosis
    Interventions:   Drug: Lenabasum 5 mg;   Drug: Lenabasum 20 mg;   Other: Placebo oral capsule
    Sponsor:   Corbus Pharmaceuticals Inc.
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: CP-690,550 (tofacitinib);   Other: placebo
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Immunoglobulin A Nephropathy
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Intervention:   Drug: Tofacitinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Anifrolumab;   Drug: Placebo
    Sponsors:   AstraZeneca;   Parexel
    Recruiting

  • Condition:   Diabetes Mellitus, Type 1
    Intervention:  
    Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Allergy and Infectious Diseases (NIAID);   National Center for Research Resources (NCRR);   Juvenile Diabetes Research Foundation;   American Diabetes Association
    Recruiting

  • Condition:   Rheumatoid Arthritis Interstitial Lung Disease
    Interventions:   Drug: Pirfenidone;   Drug: Placebo
    Sponsor:   Ivan O. Rosas
    Recruiting

  • Conditions:   Multiple Sclerosis;   Exposure During Pregnancy
    Interventions:   Drug: Dimethyl fumarate;   Drug: Peginterferon beta-1a
    Sponsor:   Biogen
    Recruiting

  • Condition:   Herpes Zoster
    Intervention:   Other: Encoding of data collected in Zoster 006 and Zoster 022 studies
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting

  • Conditions:   Systemic Lupus Erythematosus;   Lupus Nephritis
    Interventions:   Drug: KZR-616;   Drug: Placebo
    Sponsor:   Kezar Life Sciences, Inc.
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Intervention:   Drug: Baricitinib
    Sponsor:   Eli Lilly and Company
    Not yet recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Drug: BI 655064;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting


PaidClinicalTrials.orgPaidClinicalTrials.org